Feasibility Trial of Image-Guided Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease

Mallory Hacker, PhD, MSCI (Other)
Overall Status
Not yet recruiting
CT.gov ID

Study Details

Study Description

Brief Summary

The goal of this feasibility study is to evaluate the preliminary safety and efficacy of image-guided (i.e., targeting and programming the dorsolateral region of the subthalamic nucleus (STN) receiving primary motor (M1) and supplementary motor area (SMA), but not pre-SMA, input deep brain stimulation (DBS) in patients with early-stage Parkinson's disease (PD).

Condition or Disease Intervention/Treatment Phase
  • Device: active subthalamic nucleus deep brain stimulation plus optimal drug therapy
  • Device: inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy

Study Design

Study Type:
Anticipated Enrollment :
50 participants
Intervention Model:
Parallel Assignment
Single (Outcomes Assessor)
Masking Description:
motor scores will be blindly rated by an independent movement disorders neurologist who will be unaware of treatment assignment, ON vs OFF treatment status, or visit sequence
Primary Purpose:
Official Title:
A Prospective, Randomized Feasibility Clinical Trial Evaluating Image-Guided Bilateral Stimulation of the Dorsolateral Subthalamic Nucleus Receiving Hyperdirect (Primary Motor and Supplementary Motor Area) Input in Subjects With Early-Stage Parkinson's Disease
Anticipated Study Start Date :
Dec 1, 2025
Anticipated Primary Completion Date :
Apr 30, 2029
Anticipated Study Completion Date :
Aug 30, 2029

Arms and Interventions

Arm Intervention/Treatment
Experimental: active image-guided subthalamic nucleus deep brain stimulation plus optimal drug therapy

active subthalamic nucleus deep brain stimulation; plus optimal drug therapy

Device: active subthalamic nucleus deep brain stimulation plus optimal drug therapy
active subthalamic nucleus deep brain stimulation (DBS) plus optimal drug therapy

Active Comparator: inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy

inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy

Device: inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy
optimal drug therapy alone with DBS device turned off

Outcome Measures

Primary Outcome Measures

  1. frequency and severity of adverse events [24 months]

    frequency or severity of adverse events

  2. frequency and severity of adverse cognitive outcome [24 months]

    decline from baseline at ≥ 1.5 SD (modest) and ≥ 2.0 (substantial) in tests comprising a comprehensive neuropsychological battery

Secondary Outcome Measures

  1. Stopped or Reversed Motor Progression [24 months]

    proportion of subjects with stopped or reversed motor progression

Eligibility Criteria


Ages Eligible for Study:
50 Years to 75 Years
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  1. A clinical diagnosis of idiopathic Parkinson's disease (PD). The diagnosis will be based upon the presence of at least two of the three cardinal motor signs of this disorder (akinesia/bradykinesia, rest tremor, and rigidity) with at least one of the signs being rest tremor or bradykinesia.

  2. Clear and dramatic beneficial response to dopaminergic therapy, defined as ≥30% in UPDRS III with administration of the patient's medication during the screening neurological examination.

  3. Hoehn and Yahr (H&Y) stage II when OFF medication.

  4. No contraindications to surgery (i.e., subject does not have uncontrollable medical or psychiatric illness; Exclusion Criteria).

  5. Age between 50 and 75 years old.

  6. Dopaminergic therapy for greater than one year and less than four years.

  7. Available for follow-up for the entire duration of the study.

  8. Informed Consent (Appendix C): The subject is willing and able to provide written informed consent.

  9. MRI within normal range (Exclusion Criteria).

  10. Subjects receiving antidepressant medication used specifically for the treatment of depression must be on stable doses for at least eight weeks prior to enrolling in the study.

  11. Subjects must agree to maintain a stable regimen, if deemed medically appropriate by the treating physician, of any psychotropic medications throughout the blinded treatment phase.

Exclusion Criteria:
  1. Evidence of an alternative diagnosis or secondary parkinsonism, as suggested by:
  • Features unusual early in the clinical course (e.g., prominent postural instability, freezing phenomena, or hallucinations unrelated to medications in the first 3 years after symptom onset)

  • Dementia preceding motor symptoms

  • Neurologic signs of upper motor neuron or cerebellar involvement

  • Significant orthostatic hypotension unrelated to medications

  • Unequivocal cortical sensory loss (i.e., graphesthesia, sterognosis with intact primary sensory modalities), clear limb ideomotor apraxia, or progressive aphasia

  • Vertical supranuclear gaze palsy, or selective slowing of vertical saccades

  • Unequivocal cerebellar abnormalities on examination, such as cerebellar gait, limb ataxia, or cerebellar oculomotor abnormalities (e.g., sustained gaze-evoked nystagmus, macro square wave jerks, hypermetric saccades)

  • Documentation of a condition known to produce parkinsonism and plausibly connected to the subject's symptoms (e.g., MRI scan with evidence of significant brain atrophy, lacunar infarcts, or iron deposits in the putamen; history of stroke, exposure to toxins, or encephalitis; or neuroleptic use within the past 6 months)

  • The expert evaluating physician, based on the full diagnostic assessment, believes that an alternative syndrome is more likely than PD.

  1. Uncontrolled medical condition or clinically significant medical disease that would increase the risk of developing pre- or postoperative complications (e.g., significant cardiac or pulmonary disease, uncontrolled hypertension).

  2. Dementia as evidenced by a Dementia Rating Score of less than 123.

  3. Diagnosis of probable behavioral variant frontotemporal dementia or primary progressive aphasia.

  4. Currently active diagnosis of a major psychiatric disorder.

  5. Previous brain operation or injury.

  6. Active participation in another clinical trial for the treatment of PD.

  7. Subjects with cardiac pacemakers or medical conditions that require repeat MRI scans.

  8. Evidence of existing dyskinesias or motor fluctuations.

  9. Any current substance use disorder.

  10. Any history of recurrent or unprovoked seizures.

  11. Any prior movement disorder treatments that involved intracranial surgery or device implantation.

  12. Any other active implanted intracranial device (e.g., cochlear implant) or implanted device to treat movement disorders (e.g., duodopa pump) whether turned on or off.

  13. A condition requiring or likely to require the use of magnetic resonance imaging (MRI) or diathermy.

  14. History of suicide attempt.

  15. A female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception.

  16. Inability or unwillingness of subject to give written informed consent.

  17. Parkinsonian features restricted to the lower limbs for more than three years.

  18. Treatment with a dopamine receptor blocker or a dopamine-depleting agent in a dose and time course consistent with drug-induced parkinsonism.

  19. Normal functional neuroimaging of the presynaptic dopaminergic system, as measured by DaTSCAN.

  20. Rapid progression of gait impairment requiring regular use of a wheelchair.

  21. Early bulbar dysfunction, defined as one of severe dysphonia, dysarthria (speech unintelligible most of the time), or dysphagia (requiring soft food, nasogastric (NG) tube, or gastrostomy feeding).

  22. Inspiratory respiratory dysfunction defined as either diurnal or nocturnal inspiratory stridor or frequent inspiratory sighs.

  23. Recurrent (>1/year) falls because of impaired balance within 3 years of onset.

  24. Otherwise unexplained pyramidal tract signs, defined as pyramidal weakness or clear pathologic hyperreflexia (excluding mild reflex asymmetry in the more affected limb and isolated extensor plantar response).

  25. Bilateral symmetric parkinsonism throughout the disease course. The patient or caregiver reports bilateral symptom onset with no side predominance, and no side predominance is observed on objective examination.

Contacts and Locations


No locations specified.

Sponsors and Collaborators

  • Mallory Hacker, PhD, MSCI


None specified.

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Mallory Hacker, PhD, MSCI, Assistant Professor of Neurology, Vanderbilt University Medical Center
ClinicalTrials.gov Identifier:
Other Study ID Numbers:
  • G220314
First Posted:
Aug 24, 2023
Last Update Posted:
Aug 25, 2023
Last Verified:
Aug 1, 2023
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 25, 2023